Nuo Therapeutics
207A Perry Parkway
Suite 1
Gaithersburg
Maryland
20877
United States
Tel: 1-866-298-6633
Fax: 1-240-499-2690
Website: http://www.nuot.com/
37 articles about Nuo Therapeutics
-
Nuo Therapeutics Selected to Exhibit Aurix® System at Vizient Innovative Technology Exchange
6/26/2023
Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”) announced today it has been selected to exhibit the Aurix® System, the first platelet rich plasma (PRP) device indicated for chronic diabetic wounds, at the Vizient Innovative Technology Exchange.
-
Nuo Therapeutics’ Aurix® System Added To Wound Care Formulary Of Wound Care Advantage
6/22/2023
Nuo Therapeutics, Inc., a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, is pleased to announce that Wound Care Advantage, the nation’s leading wound care consulting firm has added the Aurix® System to its formulary.
-
Nuo Therapeutics Provides Corporate and Business Update
8/30/2022
Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo” or the “Company”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced today an initial corporate and business update since re-establishing fully available commercial operations in the second quarter of this year.
-
Nuo Therapeutics Responds to Mini-Tender Offer
2/4/2022
Nuo Therapeutics, Inc. (“Nuo” or the “Company”) announced that it is aware of an unsolicited “mini-tender” offer by Alternative Liquidity Index, LP to purchase up to 1,820,000 shares of Nuo common stock, approximately 4.9% of the outstanding shares, at $0.01 per share.
-
Nuo Therapeutics Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services
4/20/2021
Nuo Therapeutics, Inc. (OTC Pink: AURX) ("Nuo" or the "Company"), today announced the recent publication of the final decision memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). On April 13, 2021 , Centers for Medicare & Medicaid Services (CMS) concluded in its final coverage decision memo
-
Nuo Therapeutics Announces Recapitalization and Exchange Agreement that Simplifies Capital Structure
10/6/2020
Nuo Therapeutics, Inc. (OTC Pink: AURX) ("Nuo" or the "Company"), today announced the closing of a recapitalization and exchange agreement between the Company, Deerfield Management and affiliates thereof (Deerfield Investors), and senior secured noteholders (Noteholders) whereby the Series A Preferred Stock held by the Deerfield Investor
-
Nuo Therapeutics Provides Update on Ongoing Interactions with Centers for Medicare & Medicaid Services
3/22/2019
Nuo Therapeutics, Inc., provided an update on ongoing interactions with Centers for Medicare & Medicaid Services' Coverage and Analysis Group representatives.
-
Nuo Therapeutics Announces Corporate Update Conference Call
1/15/2019
Nuo Therapeutics, Inc. (OTCQB: AURX) ("Nuo" or the "Company"), today announced plans to conduct a conference call to provide a corporate update and respond to questions, particularly with respect to steps it is taking as a result of its discussions with representatives of the Coverage and Analysis Group (CAG) of the Centers for Medicare & Medicaid Services.
-
Nuo Therapeutics Receives Advisory Opinion Waiver For Medicare Part B Co-Payments For Patients In Aurix CED Clinical Studies
7/5/2017
-
Nuo Therapeutics Restructures Series A Preferred Stock With Deerfield
6/13/2017
-
Court Approves Nuo Therapeutics's Bankruptcy Plan
3/30/2016
-
Nuo Therapeutics Files for Chapter 11
1/27/2016
-
Nuo Therapeutics Announces Senior Management Change And Provides Limited Corporate Update
1/12/2016
-
Nuo Therapeutics Announces Execution Of Second Limited Consent With Deerfield Management Through December 17, 2015
12/7/2015
-
Nuo Therapeutics Announces Execution Of Limited Consent With Deerfield Management Through December 4, 2015
11/13/2015
-
Nuo Therapeutics Announces 3rd Quarter 2015 Financial Results
11/13/2015
-
Nuo Therapeutics To Hold Third Quarter 2015 Conference Call On Friday, November 13 At 8:00 A.M. Eastern Time
11/4/2015
-
Nuo Therapeutics Responds To Favorable CMS Hospital Outpatient Payment Final Ruling For Aurix System
11/2/2015
-
Nuo Therapeutics Executes Amended Licensing Agreement With Arthrex
10/20/2015
-
Nuo Therapeutics Launches Educational Program To Support Wound Care Centers In Transition To ICD-10
9/14/2015